Page 105 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors
P. 105

Distribution of PSMA-ligand in salivary and lacrimal glands on PET/CT
 Figure 2: Anterior projection overview of combined PSMA PET/CT (left) and PSMA PET (right), showing
tracer uptake in healthy salivary, seromucous, and lacrimal glands in a patient with prostate cancer and no 6 apparent metastatic disease. LG, lacrimal gland; NP, nasal and nasopharyngeal mucosa; PW, pharyngeal
wall; PAL, soft palate; PG, parotid gland; SM, submandibular gland; SL, sublingual gland; SG, supraglottic
larynx.
Figure 3: Low dose CT (left), PET/CT (middle) and PET (right) images of the head and neck, showing 68Ga- HBED-CC-Glu-NH-CO-NH-Lys(Ahx) uptake in healthy salivary, seromucous, and lacrimal glands in a patient with prostate cancer and no apparent metastatic disease. LG, lacrimal gland; NC, nasal cavity mucosa; NP, nasopharyngeal mucosa; PW, pharyngeal wall; PAL, soft palate; PG, parotid gland; SM, submandibular gland; SL, sublingual gland; SG, supraglottic larynx.
  103
 



























































































   103   104   105   106   107